Compare Fabrinet (FN) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fabrinet vs Revvity Inc — how do they compare? Fabrinet trades at $460 (market cap $17.44B), while Revvity Inc trades at $111.3 (market cap $12.42B). The key difference: Fabrinet is the larger of the two by market cap, and Revvity Inc pays a 0.25% dividend while Fabrinet pays none. Which is the better fit depends on your goals.
| FN | RVTY | |
|---|---|---|
Market Cap | $17.44B | $12.42B |
Sector | Technology | Technology |
52-Week High | $746.47 | $117.75 |
52-Week Low | $277.04 | $82.26 |
Enterprise Value | $16.50B | $14.91B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fabrinet (FN) trades at $460.16, down 4.69% with a bearish technical signal despite strong fundamentals. The company reported consistent earnings beats with Q1 2026 EPS of $3.72 exceeding expectations, driven by 39% YoY revenue growth in optical communications. Analyst consensus remains strongly bullish with 18 buy ratings and a $733 price target, though technical indicators show selling pressure with support at $448.
The outlook remains positive given Fabrinet's strategic position in AI infrastructure and optical communications, with projected revenue growth to $4.2B in 2026. Key risks include premium valuation multiples and supply chain constraints, but the debt-free balance sheet and expanding margins support long-term growth potential in the AI-driven data center market.
RVTY trades at $111.40, up 0.17% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company maintains stable revenue around $2.9B with an 8.26% net income margin, though its P/E ratio of 53.53 suggests premium valuation. Recent news highlights AI integration advances and FDA clearances, supporting growth initiatives.
Outlook is cautiously optimistic with strong analyst buy ratings (51.72%) and a $111.43 consensus target, but high valuation and margin pressures pose risks. Earnings on August 4, 2026, will be critical for confirming growth trajectory amid competitive and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fabrinet
Fabrinet provides advanced optical and electromechanical manufacturing services to original equipment manufacturers. It specializes in complex products for telecom, automotive, and medical industries.
Read more on FN →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
